MCID: MTH007
MIFTS: 47

Methemoglobinemia

Categories: Blood diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Methemoglobinemia

MalaCards integrated aliases for Methemoglobinemia:

Name: Methemoglobinemia 12 75 37 55 6 44 15 40 72

Classifications:



External Ids:

Disease Ontology 12 DOID:10783
KEGG 37 H00235
ICD9CM 35 289.7
MeSH 44 D008708
NCIt 50 C34817
SNOMED-CT 68 38959009
ICD10 33 D74 D74.9
UMLS 72 C0025637

Summaries for Methemoglobinemia

KEGG : 37
Hereditary methemoglobinemia is an autosomal recessive disorder characterized by NADH-cytochrome b5 reductase deficiency.

MalaCards based summary : Methemoglobinemia is related to hereditary methemoglobinemia and acquired methemoglobinemia, and has symptoms including cyanosis An important gene associated with Methemoglobinemia is CYB5R3 (Cytochrome B5 Reductase 3), and among its related pathways/superpathways are Amino sugar and nucleotide sugar metabolism and Metabolism. The drugs Lidocaine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart.

Wikipedia : 75 Methemoglobinemia is a condition caused by elevated levels of methemoglobin in the blood. Methemoglobin... more...

Related Diseases for Methemoglobinemia

Diseases in the Methemoglobinemia family:

Methemoglobinemia, Beta Type Methemoglobinemia, Alpha Type
Congenital Methemoglobinemia Hereditary Methemoglobinemia
Acquired Methemoglobinemia

Diseases related to Methemoglobinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)
# Related Disease Score Top Affiliating Genes
1 hereditary methemoglobinemia 34.4 HBG2 CYB5R3 CYB5A
2 acquired methemoglobinemia 33.8 HBG2 G6PD CYB5R3
3 congenital methemoglobinemia 33.3 HBG2 G6PD CYB5R3 CYB5A
4 hemoglobinemia 30.2 HP HBB
5 beta-thalassemia 29.9 HBG2 HBB G6PD
6 hemolytic anemia 29.9 HP HBG2 HBB G6PD
7 anemia, nonspherocytic hemolytic, due to g6pd deficiency 29.8 HP G6PD
8 deficiency anemia 29.7 HP HBG2 HBB G6PD
9 glucosephosphate dehydrogenase deficiency 29.7 HP HBG2 HBB G6PD
10 sickle cell anemia 29.7 HBG2 HBB G6PD
11 hemoglobinopathy 29.7 HP HBB
12 bilirubin metabolic disorder 29.4 HP G6PD
13 alpha-thalassemia 28.6 HP HBG2 HBB G6PD
14 malaria 28.6 HP HBB GSR G6PD
15 methemoglobinemia due to deficiency of methemoglobin reductase 12.9
16 methemoglobinemia and ambiguous genitalia 12.8
17 methemoglobinemia, beta-globin type 12.7
18 methemoglobinemia, beta type 12.5
19 methemoglobinemia, alpha type 12.5
20 obsolete: recessive hereditary methemoglobinemia type 1 12.2
21 obsolete: recessive hereditary methemoglobinemia type 2 12.2
22 cyanosis, transient neonatal 11.0
23 diarrhea 10.4
24 methemoglobin reductase deficiency 10.4
25 ocular motor apraxia 10.4
26 hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome 10.4 HBG2 HBB
27 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 10.4 HBG2 HBB
28 sulfhemoglobinemia 10.4
29 kidney disease 10.4
30 leprosy 3 10.3
31 metabolic acidosis 10.3
32 respiratory failure 10.3
33 hansen's disease 10.3
34 fetal hemoglobin quantitative trait locus 1 10.3 HBG2 HBB
35 acute kidney failure 10.3
36 pulmonary embolism 10.2
37 blood protein disease 10.2 HBG2 HBB
38 autosomal recessive disease 10.2
39 thalassemia 10.2
40 pneumocystosis 10.2
41 visual epilepsy 10.2
42 gastroenteritis 10.2
43 hypoxia 10.2
44 seizure disorder 10.2
45 posttransplant acute limbic encephalitis 10.2
46 ariboflavinosis 10.1 GSR CYB5A
47 dermatitis herpetiformis, familial 10.1
48 diabetes mellitus, ketosis-prone 10.1
49 lymphocytic leukemia 10.1
50 hyperuricemia 10.1

Graphical network of the top 20 diseases related to Methemoglobinemia:



Diseases related to Methemoglobinemia

Symptoms & Phenotypes for Methemoglobinemia

UMLS symptoms related to Methemoglobinemia:


cyanosis

Drugs & Therapeutics for Methemoglobinemia

Drugs for Methemoglobinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Racepinephrine Approved Phase 4 329-65-7 838
4
Prilocaine Approved Phase 4 721-50-6 4906
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
tannic acid Approved Phase 4 1401-55-4
7
Adenosine Approved, Investigational Phase 4 58-61-7 60961
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
11
Methylene blue Approved, Investigational Phase 4 61-73-4
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13 Pharmaceutical Solutions Phase 4
14 Anti-Infective Agents Phase 4
15 Anti-Bacterial Agents Phase 4
16 Sodium Channel Blockers Phase 4
17 Diuretics, Potassium Sparing Phase 4
18 Epinephryl borate Phase 4
19 Anti-Arrhythmia Agents Phase 4
20 Carticaine Phase 4
21 Hypnotics and Sedatives Phase 4
22 Anesthetics, General Phase 4
23 Anesthetics, Intravenous Phase 4
24 Natriuretic Agents Phase 4
25 diuretics Phase 4
26 Anesthetics Phase 4
27 Anesthetics, Local Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Central Nervous System Depressants Phase 4
30 Analgesics, Opioid Phase 4
31 Analgesics Phase 3
32 Lidocaine, Prilocaine Drug Combination Phase 3
33 Neurotransmitter Agents Phase 3
34 Respiratory System Agents Phase 3
35 Anti-Asthmatic Agents Phase 3
36 Autonomic Agents Phase 3
37 Bronchodilator Agents Phase 3
38 Antioxidants Phase 3
39 Free Radical Scavengers Phase 3
40 Protective Agents Phase 3
41 Endothelium-Dependent Relaxing Factors Phase 3
42 Vasodilator Agents Phase 3
43
leucovorin Approved Phase 1 58-05-9 143 6006
44
Dapsone Approved, Investigational Phase 1 80-08-0 2955
45
Primaquine Approved Phase 1 90-34-6 4908
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
47 Folic Acid Antagonists Phase 1
48 Vitamin B9 Phase 1
49 Antiparasitic Agents Phase 1
50 Folate Phase 1

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Topical Pharyngeal Anaesthesia With Articaine for Gastroscopy. A Randomized Double-blind Study on Volunteers Completed NCT01350050 Phase 4 articaine
2 Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation Completed NCT00732537 Phase 4 inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
3 Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's Completed NCT02507440 Phase 4 Lidocaine;Placebo;Propofol
4 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
5 Open Label Clinical Study to Evaluate the Safety and Efficacy of ProvayBlueTM (Methylene Blue) for the Treatment of Acquired Methemoglobinemia Recruiting NCT03395223 Phase 4 Methylene Blue
6 The Effect of Local Infiltration of Liposomal Bupivacaine on Opioid Consumption at Time of Cesarean Delivery: A Randomized Controlled Trial Not yet recruiting NCT03907813 Phase 4 Exparel
7 Analgesia for Neonatal Circumcision: A Randomized Controlled Clinical Trial of EMLA Versus Combination of EMLA, Sucrose and Dorsal Penile Nerve Block or Ring Block Completed NCT02990364 Phase 3 Sucrose;Lidocaine;EMLA Topical Product
8 The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure Terminated NCT00005776 Phase 3 Inhaled nitric oxide;Placebo
9 Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure Terminated NCT00005773 Phase 3 Inhaled Nitric Oxide;Standard iNO therapy
10 A Pilot, Single Center Prospective, With Parallel Groups, Controlled and Open to Evaluate the Efficacy of Nitric Oxide for Inhalation in Lung Donors and in the Prevention of Reperfusion Injury. Completed NCT00570245 Phase 2 Nitric oxide;Nitric oxide
11 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
12 A Phase II Study of Topical Sodium Nitrite in Patients With Sickle Cell and Leg Ulcers Recruiting NCT02863068 Phase 2 Topical Sodium Nitrite
13 A One-Period, Single-Dose, Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Injection USP Following a 1 mg/kg Intravenous Dose in Healthy Adult Volunteers Completed NCT02478281 Phase 1 Methylene Blue
14 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
15 Open Label Randomized Controlled Trial Pharmacokinetic and Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency Completed NCT01668433 Phase 1 Regimens (Primaquine, Methylene blue)
16 Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects Completed NCT00000740 Phase 1 Sitamaquine
17 A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax Completed NCT01780753 Phase 1 Primaquine
18 A Phase I Study of the Use of Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Hemolytic Disorders Completed NCT01316796 Phase 1 Sodium Nitrite Cream
19 Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Long-Term Intravenous Nitrite Infusion in Healthy Volunteers Completed NCT00103025 Phase 1 Sodium Nitrite;Sodium Nitrite Injection
20 Methemoglobinemia After Liposuction Under Tumescent Local Anesthesia - Timecourse and Diagnostics by Pulse Oximetry and Blood Gas Analysis. Completed NCT01766999
21 Accuracy of Detection of Methemoglobin With Pulse Oximetry Completed NCT03869840
22 Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia Completed NCT00993694 chemotherapy;dapsone
23 Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine Completed NCT01402869 4% prilocaine plain;2% Lidocaine with 1:100,000 epinephrine
24 A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation Completed NCT02305550
25 Prospective Assessment of Relapse Characteristics of Plasmodium Ovale and Antimalarial Treatment Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria in Gabon Completed NCT02528279 Coartem
26 Use of Methylene Blue in Acquired Methemoglobinemia: Prospective Observational Registry (metHb) Recruiting NCT03542760 Methylene Blue
27 A Comparison of Amethocaine Creams Versus Liposomal Lidocaine Cream as Pain Reliever Prior to Venipuncture in Children at the Paediatric Emergency Department. Withdrawn NCT00353002 Ametop (4% Amethocaine cream );Maxilene (4% Liposomal Lidocaine)

Search NIH Clinical Center for Methemoglobinemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ascorbic Acid
Ascorbic Acid Powder
Methylene blue
Sodium Ascorbate

Cochrane evidence based reviews: methemoglobinemia

Genetic Tests for Methemoglobinemia

Anatomical Context for Methemoglobinemia

MalaCards organs/tissues related to Methemoglobinemia:

41
Lung, Testes, Heart, Brain, Liver, Skin, Kidney

Publications for Methemoglobinemia

Articles related to Methemoglobinemia:

(show top 50) (show all 2268)
# Title Authors PMID Year
1
Methemoglobinemia presenting in a circumcised baby following application of prilocaine: a case report. 9 38
20181170 2010
2
[Acquired methemoglobinemia--case report]. 9 38
20306428 2010
3
A novel mutation in type II methemoglobinemia. 9 38
19471045 2010
4
A novel L218P mutation in NADH-cytochrome b5 reductase associated with type I recessive congenital methemoglobinemia. 9 38
19579085 2009
5
Intraoperative diagnosis of unsuspected methemoglobinemia due to low pulse oximetry values. 9 38
19617227 2009
6
A rare cause of mental motor retardation: recessive congenital methemoglobinemia type II. 9 38
19480335 2009
7
Methemoglobinemia related to local anesthetics: a summary of 242 episodes. 9 38
19224791 2009
8
Methemoglobinemia due to application of prilocaine during circumcision and the effect of ascorbic acid. 9 38
19013416 2008
9
Topical benzocaine-induced methemoglobinemia in the pediatric population. 9 38
18971079 2008
10
Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient. 9 38
18561168 2008
11
[Establishment of a cellular model with human NADH-cytochrome b5 reductase deficiency via RNA interference]. 9 38
18683136 2008
12
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. 9 38
17851637 2008
13
[Association of methemoglobinemia and glucose-6-phosphate dehydrogenase deficiency in malaria patients treated with primaquine]. 9 38
17992408 2007
14
Severe methemoglobinemia and syncope in a patient with glucose-6-phosphate dehydrogenase deficiency. 9 38
17939637 2007
15
The role of methemoglobinemia in early and late complicated pregnancy. 9 38
17112681 2007
16
Rediscovery of the susceptibility of G6PD deficient persons to methemoglobinemia from oxidant drugs, and to hemolysis from methylene blue. 9 38
16917918 2007
17
Severe methemoglobinemia complicating topical benzocaine use during endoscopy in a toddler: a case report and review of the literature. 9 38
16585290 2006
18
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. 9 38
16724869 2006
19
Hemolysis and methemoglobinemia secondary to rasburicase administration. 9 38
16204390 2005
20
Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. 9 38
16212642 2005
21
A case with quadriparetic cerebral palsy and cyanosis: congenital methemoglobinemia. 9 38
16087059 2005
22
Methemoglobinemia induced by topical vaginal sulfanilamide cream in a patient with cervical cancer: a case report. 9 38
15907987 2005
23
Prophylactic methylene blue in a patient with congenital methemoglobinemia. 9 38
15753496 2005
24
Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. 9 38
15390276 2005
25
Prolonged hemolysis and methemoglobinemia following organic copper fungicide ingestion. 9 38
15587250 2004
26
Prilocaine plasma levels and methemoglobinemia in patients undergoing tumescent liposuction involving less than 2,000 ml. 9 38
15870963 2004
27
[Methemoglobinemia due to prilocaine after plexus anesthesia. Reduction by prophylactic administration of ascorbic acid?]. 9 38
14992088 2003
28
The structure of the S127P mutant of cytochrome b5 reductase that causes methemoglobinemia shows the AMP moiety of the flavin occupying the substrate binding site. 9 38
14609324 2003
29
Severe methemoglobinemia after transesophageal echocardiography. 9 38
12756430 2003
30
Anesthetic management of a patient with methemoglobinemia. 9 38
12911193 2003
31
Methemoglobinemia following unintentional ingestion of sodium nitrite--New York, 2002. 9 38
12186221 2002
32
Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia. 9 38
11824767 2002
33
Metoclopramide-induced methemoglobinemia in a patient with co-existing deficiency of glucose-6-phosphate dehydrogenase and NADH-cytochrome b5 reductase: failure of methylene blue treatment. 9 38
11418378 2001
34
Molecular basis of recessive congenital methemoglobinemia, types I and II: Exon skipping and three novel missense mutations in the NADH-cytochrome b5 reductase (diaphorase 1) gene. 9 38
11295830 2001
35
A Thai boy with hereditary enzymopenic methemoglobinemia type II. 9 38
11215870 2000
36
[Acute dapsone exposure and methemoglobinemia in children: treatment with multiple doses of activated charcoal with or without the administration of methylene blue] 9 38
14647658 2000
37
Metoclopramide-induced methemoglobinemia in an adult. 9 38
10870338 2000
38
A novel mutation in the NADH-cytochrome b5 reductase gene of a Chinese patient with recessive congenital methemoglobinemia. 9 38
10807796 2000
39
Combined effects of inhaled nitric oxide (iNO) and oxidant agents on the production of methemoglobinemia in newborn piglets. 9 38
10809284 2000
40
A case of methemoglobinemia type II due to NADH-cytochrome b5 reductase deficiency: determination of the molecular basis. 9 38
10874300 2000
41
[A novel point mutation in NADH-cytochrome b5 reductase gene]. 9 38
11721397 1999
42
Hb Chile [beta28(B10)Leu-->Met]: an unstable hemoglobin associated with chronic methemoglobinemia and sulfonamide or methylene blue-induced hemolytic anemia. 9 38
10335980 1999
43
Antibody-based spot test for NADH-cytochrome b5 reductase activity for the laboratory diagnosis of congenital methemoglobinemia. 9 38
9620466 1998
44
Methemoglobinemia induced by methylene blue pertubation during laparoscopy. 9 38
9605379 1998
45
A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. 9 38
9445511 1998
46
Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. 9 38
9347001 1997
47
Methodologic problems encountered with cooximetry in methemoglobinemia. 9 38
9298047 1997
48
Methemoglobinemia caused by topical benzocaine. 9 38
9324196 1997
49
Methemoglobinemia induced by an over-the-counter medication. 9 38
8913407 1996
50
Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. 9 38
8757424 1996

Variations for Methemoglobinemia

ClinVar genetic disease variations for Methemoglobinemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 subset of 22 genes:FLCN ; RAI1 GRCh37/hg19 17p11.2(chr17: 16936603-18184130) copy number loss Pathogenic 17:16936603-18184130 :0-0

Expression for Methemoglobinemia

Search GEO for disease gene expression data for Methemoglobinemia.

Pathways for Methemoglobinemia

Pathways related to Methemoglobinemia according to KEGG:

37
# Name Kegg Source Accession
1 Amino sugar and nucleotide sugar metabolism hsa00520

Pathways related to Methemoglobinemia according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 NAT2 HBB GSR G6PD CYP3A4 CYP2E1
2
Show member pathways
12.63 NAT2 GSR CYP3A4 CYP2E1 CYB5R3 CYB5A
3 12.14 HBB G6PD CYP3A4
4
Show member pathways
11.33 CYP3A4 CYP2E1
5
Show member pathways
11.3 CYP3A4 CYP2E1
6
Show member pathways
11.05 CYP3A4 CYP2E1
7 10.98 CYP3A4 CYP2E1
8 10.78 CYP3A4 CYP2E1
9 10.67 CYP3A4 CYP2E1
10 10.58 GSR G6PD
11
Show member pathways
10.55 NAT2 CYP3A4 CYP2E1
12 9.4 G6PD CYB5R3 CYB5A

GO Terms for Methemoglobinemia

Cellular components related to Methemoglobinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular membrane-bounded organelle GO:0043231 9.67 G6PD CYP3A4 CYP2E1 CYB5A
2 blood microparticle GO:0072562 9.5 HP HBG2 HBB
3 tertiary granule lumen GO:1904724 9.4 HP HBB
4 organelle membrane GO:0031090 9.33 CYP3A4 CYP2E1 CYB5A
5 endocytic vesicle lumen GO:0071682 9.26 HP HBB
6 hemoglobin complex GO:0005833 9.13 HBG2 HBB CYB5R3
7 haptoglobin-hemoglobin complex GO:0031838 8.8 HP HBG2 HBB

Biological processes related to Methemoglobinemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.58 CYP3A4 CYP2E1 CYB5R3
2 response to hydrogen peroxide GO:0042542 9.56 HP HBB
3 positive regulation of cell death GO:0010942 9.55 HP HBB
4 glutathione metabolic process GO:0006749 9.54 GSR G6PD
5 cholesterol biosynthetic process GO:0006695 9.52 G6PD CYB5R3
6 hydrogen peroxide catabolic process GO:0042744 9.51 HBG2 HBB
7 xenobiotic metabolic process GO:0006805 9.5 NAT2 CYP3A4 CYP2E1
8 exogenous drug catabolic process GO:0042738 9.49 CYP3A4 CYP2E1
9 drug metabolic process GO:0017144 9.48 CYP3A4 CYP2E1
10 long-chain fatty acid biosynthetic process GO:0042759 9.46 CYP3A4 CYP2E1
11 oxygen transport GO:0015671 9.43 HBG2 HBB
12 oxidation-reduction process GO:0055114 9.43 GSR G6PD CYP3A4 CYP2E1 CYB5R3 CYB5A
13 L-ascorbic acid metabolic process GO:0019852 9.37 CYB5R3 CYB5A
14 heterocycle metabolic process GO:0046483 9.26 CYP3A4 CYP2E1
15 monoterpenoid metabolic process GO:0016098 9.16 CYP3A4 CYP2E1
16 cellular oxidant detoxification GO:0098869 8.92 HP HBG2 HBB GSR

Molecular functions related to Methemoglobinemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.55 GSR G6PD CYP3A4 CYP2E1 CYB5R3
2 flavin adenine dinucleotide binding GO:0050660 9.52 GSR CYB5R3
3 monooxygenase activity GO:0004497 9.51 CYP3A4 CYP2E1
4 NADP binding GO:0050661 9.49 GSR G6PD
5 peroxidase activity GO:0004601 9.48 HBG2 HBB
6 steroid hydroxylase activity GO:0008395 9.46 CYP3A4 CYP2E1
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.43 CYP3A4 CYP2E1
8 oxygen carrier activity GO:0005344 9.4 HBG2 HBB
9 organic acid binding GO:0043177 9.37 HBG2 HBB
10 heme binding GO:0020037 9.35 HBG2 HBB CYP3A4 CYP2E1 CYB5A
11 haptoglobin binding GO:0031720 9.32 HBG2 HBB
12 hemoglobin binding GO:0030492 9.26 HP HBB
13 oxygen binding GO:0019825 8.92 HBG2 HBB CYP3A4 CYP2E1

Sources for Methemoglobinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....